| Active substance | Epcoritamab |
| Holder | AbbVie Belgium SA/NV |
| Status | Runing |
| Indication | Third line and subsequent lines of treatment (3rd +) Relapse/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 30/10/2023 |